Pfiz­er, Astel­las say Xtan­di drug com­bo re­duces risk of metas­ta­sis, death in prostate can­cer by 58%

Pfiz­er and Astel­las tout­ed more de­tailed da­ta over the week­end on their drug Xtan­di in a type of prostate can­cer, which the com­pa­nies say show the po­ten­tial for Xtan­di to be added to the stan­dard of care if a la­bel ex­pan­sion is ap­proved.

In the Phase III EM­BARK tri­al, the com­pa­nies test­ed out Xtan­di plus le­upro­lide and Xtan­di as a monother­a­py against place­bo plus le­upro­lide in men with non-metasta­t­ic hor­mone-sen­si­tive prostate can­cer with high-risk bio­chem­i­cal re­cur­rence (BCR).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.